Tetraphase Pharmaceuticals, Inc. (TTPH) insider have most recently took part in a trading activity. On Nov 29, 2017 Gage L Patrick, Director bought 3,880 shares having total worth of $25,026 at the price of $6.45 per share, following the transaction a total of 38,880 shares owned by Gage L Patrick. Before this latest buy, Gage L Patrick purchased TTPH at 1 other times during the past twelve months, for a total investment of $82,390 at an average of $7.49 per share.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 sell activities .Furthermore, over the past 12 months , the stock was traded 4 times by insiders. In 3 of these trades, the insider was a seller while an employee of the company was the buyer in 1 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) traded down 1.71% on Dec 1, 2017, hitting $6.31. 501,239 shares of the company’s stock traded hands. Tetraphase Pharmaceuticals, Inc. has a 52 week low of $3.25 and a 52 week high of $9.22. The company’s market cap is $145 million.
Tetraphase Pharmaceuticals, Inc. (TTPH) last announced its earnings results on Nov 2, 2017. The company reported -0.63 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.67 by $0.04. The company had revenue of $4 million for the quarter, compared to the consensus estimate of $1 million. During the same quarter in the previous year, the company posted -0.58 earnings per share. The company’s revenue for the quarter was up 378% on a year-over-year basis.
|earnings per share||-0.63||-0.83||-0.61||-0.50||-0.49||-0.72||-0.66||-0.69||-0.55||-0.71|
Tetraphase Pharmaceuticals Inc is incorporated under the laws of the State of Delaware on July 7, 2006. The Company is a clinical stage biopharmaceutical company using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. The Company’s product candidate eravacycline is a fully synthetic tetracycline derivative. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. The Company’s competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018